

	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 200.1079CON7	APPLICATION NO 10/057,632			
	LIST OF PRIOR ART CITED BY APPLICANT						
	APPLICANT Ronald M. BURCH et al.						
	FILING DATE January 25, 2002		GROUP 1639				
(Use several sheets if necessary)							
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A01	4,690,927	09/01/1987	Voss et al.			
	A02	4,844,907	07/04/1989	Elger et al.			
	A03	4,669,937	03/11/1986	Baker et al.	Duplicate: on 1/2/2004 PTO-892		
	A04	5,190,947	03/02/1993	Riess et al.			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

A05	Statement Before the Food and Drug Administration's Arthritis Drugs Advisory Committee on the Nonsteroidal anti-inflammatory Drug Celecoxib. (HRG Publication #1465); December 1, 1998; obtained from http://www.citizen.org/publications/print_release.cfm?ID=6653 on October 28, 2008.
A06	NDA 020938 Approval letter and label April 13, 2000; obtained from http://www.accessdata.fda.gov on October 16, 2008
A07	NDA 20-938 Medical Review, completed August 31, 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008
A08	NDA 20-938 Pharmacology Review(s), completed September 17, 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008
A09	NDA 20-938 Clinical Pharmacology and Biopharmaceutics Review(s), 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008
A10	NDA 20-938 Correspondence, 1998-1999; obtained from http://www.accessdata.fda.gov on October 16, 2008
A11	NDA 20-938 Administrative Documents, 1998; obtained from http://www.accessdata.fda.gov on October 16, 2008
A12	NDA 20-938 Chemistry Review(s), 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008
A13	NDA 20-938 Microbiology Review(s) 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008
A14	NDA 20-938 Statistical Review(s) 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008
A15	Therapeutics Initiative, February 1995
A16	Therapeutics Initiative, January 1997
A17	Therapeutics Initiative, January/February 2001
A18	Prescribing Points, volume 8.4, June 1999
A19	Lichtblau, L. et al., "Pharmacologic management of cancer pain in rural Minnesota," <i>J Pain Symptom Manage</i> , Vol. 12, No. 5, p. 283-9, 1996.
A20	Wollheim, F.A., "Current pharmacological treatment of osteoarthritis," <i>Drugs</i> , Vol. 52, Suppl. 3, p. 27-38, 1996.
A21	Furst, D.E., "Meloxicam: selective COX-2 inhibition in clinical practice," <i>Semin Arthritis Rheum</i> , Vol. 26, No. 6, Suppl. 1, pp. 21-7, 1997.
A22	Capasso, Anna et al. "Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum" <i>European Journal of Pharmacology</i> Vol. 330, pp. 199-204, 1997.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CG/

EXAMINER	/Christopher Gross/ (10/20/2010)	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		